Moderna’s stocks surge in pre-market on vaccine hopes. Dow futures up 500 points

Moderna’s (MRNA.US)  announced that its experimental vaccine for coronavirus showed promise in early trials. Biotech company announced that it's  early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants.  Vaccine also kept the virus that causes Covid-19 from replicating in the lungs of mice. Moderna has developed the first experimental coronavirus medicine, but an approved treatment is more than a year away.

Moderna’s (MRNA.US) stock rocketed over 28% in pre market trading. Source: xStation5

S&P500 (US500) -  Futures contracts tied to the major U.S. stock indexes rose sharply Monday, as news from a Moderna trial stoked optimism about a potential coronavirus vaccine. Source: xStation5

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.